• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Glycoproteogenomics: Setting the Course for Next-generation Cancer Neoantigen Discovery for Cancer Vaccines

    2021-12-03 09:03:30JoseAlexandreFerreiraMartaRelvasSantosAndreiaPeixotoAndreSilvaLucioLaraSantos
    Genomics,Proteomics & Bioinformatics 2021年1期

    Jose′ Alexandre Ferreira*, Marta Relvas-Santos,, Andreia Peixoto,Andre′ M.N. Silva, Lu′cio Lara Santos,3

    1 Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto 4200-072, Portugal

    2 Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto 4050-313, Portugal

    3 Porto Comprehensive Cancer Center (P.ccc), Porto 4200-072, Portugal

    4 REQUIMTE-LAQV, Department of Chemistry and Biochemistry, Faculty of Sciences of the University of Porto, Porto 4169-007, Portugal

    KEYWORDS

    Abstract Molecular-assisted precision oncology gained tremendous ground with high-throughput next-generation sequencing (NGS), supported by robust bioinformatics. The quest for genomicsbased cancer medicine set the foundations for improved patient stratification,while unveiling a wide array of neoantigens for immunotherapy.Upfront pre-clinical and clinical studies have successfully used tumor-specific peptides in vaccines with minimal off-target effects. However, the low mutational burden presented by many lesions challenges the generalization of these solutions, requiring the diversification of neoantigen sources. Oncoproteogenomics utilizing customized databases for protein annotation by mass spectrometry (MS) is a powerful tool toward this end. Expanding the concept toward exploring proteoforms originated from post-translational modifications(PTMs)will be decisive to improve molecular subtyping and provide potentially targetable functional nodes with increased cancer specificity. Walking through the path of systems biology, we highlight that alterations in protein glycosylation at the cell surface not only have functional impact on cancer progression and dissemination but also originate unique molecular fingerprints for targeted therapeutics.Moreover,we discuss the outstanding challenges required to accommodate glycoproteomics in oncoproteogenomics platforms. We envisage that such rationale may flag a rather neglected research field, generating novel paradigms for precision oncology and immunotherapy.

    Neoantigen-based cancer vaccines: status and milestones for clinical translation

    Targeted therapeutics, alone or in combination with chemo and radiotherapy, have constituted a crucial milestone in the management of cancer patients, being particularly important for those at advanced stage facing limited therapeutic options[1,2].Over the last ten years,a plethora of antibodies has been developed targeting proteins overexpressed by cancer cells,which play key roles in relevant oncogenic pathways and tumor vasculature development [3,4]. A few antibody-based treatments have already been introduced in clinical practice and many more are undergoing the late phase of clinical trials[5,6].Cancer antibodies have also been shown to inhibit cancer growth and spread by blocking key cellular processes and inducing antibody-dependent cellular cytotoxicity (ADCC),promoting cancer cell elimination[7].The introduction of antibodies capable of inhibiting checkpoint molecules responsible by immune tolerance to cancer cells such as PD-1, PD-L1,and CTLA-4 has decisively boosted cancer immunotherapy,showing effective results,especially in combination with chemo and radiotherapy [8,9].

    Currently, many worldwide reference oncological centers provide comprehensive treatment options, which are elected according to the molecular features of the targeted lesions and adjusted to the spatio-temporal evolution over the course of disease management. However, the enormous potential of antibody-based targeted therapeutics has been,to some extent,limited by off-target toxicity and high tumor molecular heterogeneity [10]. On the other hand, a pre-existing immunogenic fingerprint translated by high mutational burden appears to be a pre-requisite for effective immunotherapies, limiting the generalization of immune checkpoint inhibitors [11].

    The limitations inherent to antibody-based immunotherapy have prompted a quest for cancer neoantigens, i.e., peptides(segments of proteins)specifically found on the surface of cancer cells. Although classically associated to alterations in protein primary sequences due to non-synonymous mutations, it became widely accepted that these neoantigens may also arise from altered splicing mechanisms, gene fusions, endogenous retroelements, and other processes occurring at the genome and transcriptome levels [12–14]. Post-translational modifications (PTMs) may also decisively contribute to unique cancer molecular signatures, which can be explored to unleash immune responses against cancer cells [15,16] (Figure 1).However, at early stages of neoantigen discovery, the immunotherapy field has neglected the potential of protein neoantigens due to tremendous molecular heterogeneity and limited potential for ‘‘one fits all” pharmacological solutions[17]. In recent years, the technological readiness of highthroughput molecular characterization platforms has challenged this concept. Next-generation DNA sequencing has allowed rapid tackle of the cancer genome for mutations that have been subsequently explored in vaccine formulations [18].Moreover,mass spectrometry(MS)has been used to quantitatively characterize cancer neoantigens[19–21],and increasingly sophisticated bioinformatics tools are aiding in the real-time identification of most suited protein species to include in vaccine formulations [22]. Finally, lab-scale peptide synthesizers allow real-time production of small quantities of diverse molecules for vaccines under good manufacturing practice (GMP)conditions, providing an opportunity for vaccine production in loco [23]. Increasing numbers of improved vaccine delivery vehicles are also emerging,which are designed to boost immune responses against otherwise less immunogenic cancer neoantigens[24].So far,pre-clinical studies in mice support the excellent therapeutic potential of whole genome-based multivalent cancer vaccines for melanomas and neuroblastomas [25–28].These solutions have remarkably reduced tumor burden and,in some cases,completely eradicated tumors in animal models,while generating an immunological memory capable of preventing metastasis [25–28]. This has provided blueprints on how such approaches can be translated into clinical applications in humans. Namely, a phase I clinical trial is ongoing to evaluate the safety and effect of personalized neoantigen vaccines for pancreatic cancer based on next-generation sequencing(NGS) and major histocompatibility complex (MHC) affinity prediction algorithm (NCT03558945). The study hypothesizes that personalized neoantigen vaccines will be safe and capable of generating measurable neoantigen-specific CD4+and CD8+T cell responses.Moreover,combination therapies with immune checkpoint inhibitors have allowed to unleash previously compromised immune responses in pre-clinical trials[29,30].Such findings fostered phase I/II clinical trials focused on personalized cancer vaccines derived from mutated peptides in combination with nivolumab and ipilimumab, in patients with metastatic non-small cell lung cancer,microsatellite stable colorectal cancer, gastroesophageal adenocarcinoma, and metastaticurothelialcancer(NCT03953235and NCT03639714). These initiatives illustrate the materialization of precision oncology and will,most likely,constitute the next cornerstone in cancer management.

    While no longer considering blue-sky approaches, the efficiency of patient-tailored cancer neoantigen vaccines is still challenged by the low mutational frequency presented by many lesions[31].More strikingly,comparative genomics has shown that,in some cases,metastases present a rather limited array of mutations in comparison to primary lesions [32]. As such,extending neoantigen discovery beyond peptide identification based on genomic sequencing stands as the next logical step.The emerging field of proteogenomics, exploring customized protein sequence databases by integrating genomics and transcriptomics data,provides a unique tool to interrogate the cancer proteome [33]. In fact, the integration of genomics and transcriptomics is crucial for protein identification, bringing proteomics one step closer to the exome. Accordingly, paired genomics, transcriptomics, and proteomics data of samples from the same tumors have demonstrated that the proteome contains novel information that cannot be discerned through genomic analysis alone [34].

    An additional level of molecular complexity arises from the array of PTMs that decisively define protein biophysical and biochemical properties as well as functional roles. PTMs provide microenvironmental context and exponentially increase the number of protein species defined by the exome,leveraging a more complete view of tumor molecular heterogeneity and cancer biology [35]. Particularly, glycosylation is amongst the main PTMs of membrane proteins and it is well established that cancer cells present altered glycosylation patterns in comparison to corresponding healthy tissues [36,37]. A significant number of studies have also consensually postulated an array of glycan modifications that appear of pancarcinoma nature[38,39].Moreover,many reports advocate that such molecular features are responsible for generating unique glycopeptide signatures at the cell surface [40]. Identifying these distinctive cancer-specific glycoproteoforms will provide bispecific (at the glycan and protein levels) molecular targets, with the potential to limit off-target effects.

    Figure 1 Neoantigens generated by modifications at DNA, RNA, and protein levels as well as by PTMs Cancer cells frequently express unique protein species that are not present in healthy tissues(neoantigens), holding tremendous potential for targeted therapies and immunotherapy. Neoantigens may derived primarily from alterations in genome but also in RNA processing and other events underlying protein synthesis.Protein maturation with PTMs,such as glycosylation and phosphorylation,adds a second layer of specificity,which is valuable toward more effective targeted therapeutics.Beyond genetic alterations,epigenetic regulation plays a key role in governing gene expression as well as processing, significantly contributing to the formation of a wide array of proteoforms either directly or indirectly modulating the expression of enzymes involved in PTMs of proteins.Me,methyl;Ac,acetyl;SLeA,sialyl-LewisA; SLeX, sialyl-Lewis X; S3T, sialyl-3-T; STn, sialyl-Tn; GPI, glycosylphosphatidylinositol; PTM, post-translational modification.

    The proof of concept regarding the potential of glycanbased proteogenomics has been highlighted in two recent studies, supporting the pursuit of more comprehensive research efforts [41,42]. As such, this review focuses on illustrating the role of proteogenomics as a decisive tool for systems biology and,ultimately,precision oncology.Focus is set on the importance of addressing protein glycosylation and integrating glycomics and glycoproteomics into neoantigen discovery platforms, envisaging the generalization of cancer vaccines to tumors of distinct molecular natures.

    Oncoproteogenomics toward neoantigen discovery

    Cancer biomarker discovery has been mostly centered on the genome and transcriptome, with less, but growing emphasis,on the proteome. While the complexity of the tumor genomic background is being rapidly uncovered by large dimension sequencing studies [32,43,44], translation of its findings into resulting proteome remodeling remains poorly understood and explored. In fact, many reports disclosed a landscape of genetically relevant alterations and dysfunctional transcriptomes that reflect large numbers of non-synonymous singlenucleotide variants (SNVs), insertions and deletions (indels),alternative splicing variants, copy-number aberrations, and abnormal fusion genes [45]. However, the transcriptome frequently fails to mirror the proteome’s abundance, diversity[46,47],and consequent functional impact on tumor initiation,progression, dissemination, and response to treatment. This has limited the easy translation of elegant transcriptomederived patient stratification models into the everyday practice of most pathology laboratories. It has also delayed the identification of clinically relevant proteins for rational design of targeted therapeutics. The number of protein surrogates and/or targetable biomarkers for molecular-based patient stratification reaching the clinics remains scarce. The few successful examples include prostate-specific antigen (PSA) for detection[48],carcinoembryonic antigen(CEA)for patient management and prognosis[49],and CA125/mucin 16(MUC16),which is a diagnostic marker and holds potential for targeted therapies[50], in prostate, colon, and ovarian cancer, respectively.

    On the other side of the equation, the initial enthusiasm with oncoproteomics in the post-genomic era, which started 20 years ago,has been gradually losing ground.This is mostly due to protein identifications in conventional proteomics workflows relying on general protein databases that fail to reflect the uniqueness of the cancer transcriptome[51],limiting the breadth of identified biomarkers.Oncoproteogenomics has arisen from the pressing need to correct this discrepancy,enabling the accurate interpretation of large datasets generated by modern high-resolution mass spectrometers. Proteogenomics exploits sample-matched genomics and transcriptomics datasets to customize protein annotation, providing definitive proofs of protein translation [52]. The most used approaches for generating protein databases include whole-genome or exome sequencing, with emphasis on six-frame translation of whole genome sequences, which enables the identification of previously undiscovered exons and open reading frames [53].Available exon annotations on the human genome may also be explored to generate junction sequences for all possible exons in a gene. DNA/RNA sequencing is also available to obtain SNV data and corresponding tumor-specific protein sequences [54].

    When applied to cancer,proteogenomics is an exciting new concept, which attempts to detect tumor-specific changes in proteoforms that result from mutations or an altered transcription process, rather than solely focusing on improving proteome characterization (Figure 2). Over the past five years,these methodologies have become sufficiently mature to support the transition from proof of concept studies in cell lines and animal models to large-scale translational studies using human samples. Several examples show how oncoproteogenomics may complement and improve on the molecular subtyping and prognostication of breast [55], gastric [41],colorectal [46], and ovarian [56] tumors beyond previous genomics- and transcriptomics-based patterns. Most of these reports provide proteome-based networks highlighting functional protein nodules for targeted intervention. Furthermore,the depth of tumor proteogenomics profiling has led to the identification of breast cancer protein neoantigens that result from previously undescribed gene variants and non-coding gene regions,defying old paradigms and expanding our understanding of cancer molecular biology[20].Such molecular signatures are possibly the consequence of significant cancer genome instability and arise as strong candidates for immunotherapy.

    Despite several examples of considerable technology readiness, when facing clinical translation, some outstanding challenges persist for oncoproteogenomics. Perhaps the most pressing difficulty relates to the fact that databases of putative protein sequences derived from genomics experiments are significantly larger than those explored in conventional proteomics, which dangerously increases the probability of false positives during protein annotation.Moreover,the incorporation of large genomics datasets into proteomics poses a significant computational challenge, translated by long processing times and frequently high false discovery rates[57].This is further aggravated by the low relative abundance of peptide sequences derived from genetic abnormalities over protein species arising from genomics predictions. Alternatively,libraries inferred directly from RNA-seq, expressed sequence tag (EST), and cDNA bring us one step closer to the exome,while significantly reducing the amount of generated data in comparison to whole-genome sequencing [58]. Furthermore,transcriptome-generated databases allow the proteomic identification of RNA editing products, splice junctions, and fusion proteins. Nevertheless, oncoproteogenomics continues to be a fast-evolving field, and more detailed information on the opportunities and limitations of analytical and bioinformatics tools to assist database customization and accommodating genomics information can be found in recent reviews [59,60].Another key aspect is the capacity to translate proteogenomics data into relevant targets for immunotherapy. This aspect has been elegantly tackled by several computational pipelines to elect peptides with higher binding affinity to MHC-I molecules[61–63]. Moreover,neural networks exploiting annotated data on the binding kinetics of known peptides are being used to refine these models to estimate cancer neoantigen affinity to a wide array of different MHC classes and haplotypes,providing means for a more educated election of suitable immunogens [64–66]. However, even if a peptide has strong MHC binding prediction,this may be ineffective if upstream processing such as proteolysis prevents the actual loading of that peptide. Accordingly, several software are now available to aid prediction of proteasome specificity and protease cleavage sites, including NetChop20S, NetChopCterm, and ProteaSMM for MHC class I antigens, and PepCleaveCD4 and MHC-II-NP for MHC class II antigens,offering a second level of predicted peptide quality control [67–70]. The notion that many predicted neoantigens may never constitute proteolysis products capable of being presented by MHC has again prompted proteomics. MHC molecules and associated peptides are currently being isolated from different cancers for tandem mass spectrometry(MS/MS)identification,generating key data for training machine learning algorithms to improve neoantigen prediction [71]. The thorough accomplishment of such goals will be decisive for translating oncoproteogenomics into clinically useful targets. Finally, critical challenges persist concerning the capacity of oncoproteogenomics to infer on relevant functional mechanisms adopted by cancer systems at multiple biological scales, ultimately pinpointing key biological network nodes for intervention [72]. A plethora of reports shows that this goal requires a comprehensive understanding of PTMs [39,73]. PTMs are key for defining and regulating protein functions, degradation pathways, and even cellular locations, and many times play an essential role in the signaling pathways that define cell fate[72].PTMs,such as phosphorylation, methylation, and glycosylation, are pivotal in the rapid modulation of protein functions in response to microenvironmental cues,providing potential links between metabolic alterations and protein activity [74]. Therefore, incorporating PTMs into oncoproteogenomics setups will bring us one step closer to systems biology settings,even though at the expenses of a new set of interdisciplinary analytical challenges.

    Figure 2 Integrated multiomics data toward discovery of potential clinically relevant biomarkers and targeted therapeutics Oncoproteogenomics concerns genomics and transcriptomics data from tumor samples, which is used for generating customized databases, to support protein annotation. The inclusion of glycomics information in the workflow allows more effective protein identification by MS/MS,including glycosylation site mapping,illustrating its value to gain insight on molecular information that cannot be achieved by the other omics toward precision oncology. Overall oncoproteogenomics is supported by several bioinformatics tools,which also contributes for identification of more suitable antigens toward cancer vaccines.WGS,whole-genome sequencing;SNV,singlenucleotide variant; indel, insertion and deletion; MS/MS, tandem mass spectrometry; HexNAc, N-acetylhexosamine; Hex, hexose.

    PTMs are often of a transient nature, but exponentially increase the number of proteoforms, raising problems for accurate protein identification. Such dynamics are often accompanied by a complex and non-templated molecular organization, as is the case of glycosylation. As a result, more than half of the spectral information generated by MS/MS experiments usually remains unassigned due to the presence of PTMs, as elegantly demonstrated by Chick and his colleagues [75]. The accommodation of these subtleties requires an adaptation of conventional proteomics protocols, namely the incorporation of pre-enrichment methods and different separation techniques, inclusion of a diversified array of proteases and other enzymes prior to MS analysis, diversification of MS ionization and fragmentation methods, and dedicated bioinformatics analysis [76]. In addition, the physicochemical alterations resulting from PTMs may decisively interfere with MS-based protein identification at different levels. It is widely known that acid groups and other hydrophilic species are detrimental to ionization and might reduce the identification of modified peptides by electrospray analysis, which is used by the bulk of modern mass spectrometers [77]. Nevertheless,this effect may be significantly attenuated by the acidic buffers generally used in proteomics experiments to produce positive charged species at lower pH. It may also be compensated by the very high sensitivity and resolution of modern spectrometers,particularly when coupled to liquid chromatography(LC)operated in nano-settings. Another critical aspect is PTM site annotation.Site assignment is particularly challenging because MS/MS experiments involving modified peptides often originate fragment ions that are not accurately identifiable by the bioinformatics tools used in routine proteomics workflows.In fact, conventional proteomics search algorithms can dynamically accommodate several anticipated modifications but fail to identify peptides carrying unknown alterations[75]. And even the identification of peptides carrying expectable modifications may not be straightforward. Common database search algorithms face difficulties to score with high-confidence complex fragment ion spectra quite often containing information on PTM neutral loss or non-canonical fragmentation pathways [78]. This difficulty is generally overcome by resorting to the combination of different MS/MS fragmentation strategies[79,80].Nevertheless,recent advances in bioinformatics tools have generated reliable analytical platforms capable of supporting large dimension studies at this level. A key example is the generalization of the Byonic software,which has been used as a more reliable tool for glycoprotein and glycopeptide annotations [81,82].

    Despite such challenges,there are already some demonstrations upholding the decisive role of PTM monitoring for patient stratification.Most studies have explored phosphorylation to demonstrate its decisive role for pinpointing relevant disease-associated molecular pathways and how this information may be comprehensively fit into clinical models to improve patient management [56,83,84]. Histone acetylation has also been explored to gain insight on endometrial carcinogenesis, foreseeing new therapeutic approaches [85]. Emerging reports now point out the need to include protein glycosylation to gain insight on different levels of molecular information that cannot be deciphered by genomics, transcriptomics, and proteomics alone[37,39]. Previous studies have shown the significance of glycosylation for patient stratification and identification of novel biomarkers and therapeutic targets [41,42]. As example,altered sialylation and fucosylation have been used to improve the predictive value of PSA [86–88]. Targeting sialyl-Tn (STn) glycoforms of plasminogen in the serum of patients holds potential for non-invasive clinical diagnosis of individuals with gastric precancerous lesions [89]. Also, MUC16-STn was identified as an independent predictive biomarker of decreased response to chemotherapy in bladder cancer,whereas MUC16 and STn alone were not [90]. Furthermore,by greatly extending the number of identifiable cancerspecific proteoforms, PTMs will retrieve unforeseen cancer neoantigens to support cancer vaccine development based on a more comprehensive approach.

    Cancer glycosylation for precise cancer targeting

    Glycosylation is the most abundant and structurally complex PTM of membrane-anchored and secreted proteins. Despite presenting a non-templated structural nature, it is subjected to strict cellular regulation, rapidly responding to physiological alterations and distinct pathological contexts.As such,glycan heterogeneity reflects the harmonized activity of nucleotide sugar transporters, glycosyltransferases, and glycosidases in the endoplasmic reticulum (ER) and Golgi apparatus (GA)[36].Altered glycogene expression,loss of cellular homeostasis,including metabolic shifts impacting in nucleotide sugar availability, and alterations in subcellular localization of glycosyltransferases and glycosidases are amongst the main events driving changes in glycan chains in cancer cells [36,91]. On the other hand, loss-of-function mutations in glycogenes are not frequent and have therefore little impact on the establishment of this malignant glycophenotype [92]. The main classes of cell surface glycans are O-N-acetylgalactosamine (OGalNAc) glycans, set up in the GA through the attachment of a GalNAc to serine (Ser) or threonine (Thr), and N-glycans,initiated in the ER with the addition of an oligosaccharide moiety to an asparagine(Asn)residue in a peptide consensus sequence of Asn-X-Ser/Thr (X corresponding to any amino acid except proline) [36]. Glycans are further processed throughout the secretory pathways according to the cellular repertoire of glycosyltransferases,glycosidases,and substrates.This may comprehend branching and/or elongation of core structures, sialylation, and termination with Lewis blood group-related antigens or ABO(H) blood group determinants,amongst other epitopes. Sialic acids may be further modified by O-acetylation, and galactose (Gal) and GlcNAc by sulfation, greatly expanding the complexity of the glycome [36].Mature glycans may still experience structural remodeling by extracellular glycosyltransferases and glycosidases freely circulating in the plasma or carried by platelets, further increasing the breadth of its structural dynamics [93].It is likely that this may also occur at the surface of cancer cells in solid tumors,which has not yet been demonstrated.

    Glycans are crucial in early steps of protein biosynthesis and maturation, ensuring quality control of protein folding and contributing to define protein conformation and functional roles. Alterations in the composition of glycan chains and the distribution and the density of glycosites in proteins are common in cancer[39].Glycomics studies of different nature and involving a wide number of distinct types of cancer have consistently demonstrated that more aggressive cancer cells increase the degree of protein sialylation and N-glycan branching [36,91]. Concomitantly, glycoproteins may lose the capacity to present elongated O-glycans,thus acquiring simple cell glycophenotypes translated by the accumulation of short glycoforms such as the Tn,STn,and T antigens[94–96].These events induce major phenotypic alterations toward enhanced cell motility and cell invasion and activate relevant oncogenic pathways, namely the EGFR and ErbB2 receptors [95–99].The expression of truncated glycans further impacts the interactions of cancer cells with the immune system. Examples include STn antigen recognition by Siglec-15 on macrophages and dendritic cells, and sialyl-T (ST) antigen recognition by Siglec-9 on neutrophils and Siglec-7 on natural killer cells[100]. These interactions trigger an array of inhibitory signals on antigen-presenting cells, ultimately precluding T cellmediated responses against tumor cells, as demonstrated by recent studies[101,102].It is likely that a deeper understanding of functional interactions between glycans and glycoconjugates with immune system intermediates may constitute the next cornerstone for immune checkpoint inhibition and, potentially, a more rational design of cancer vaccines. Cancer cells also often overexpress sialylated Lewis antigens such as sialyl-Lewis A (SLeA) and X (SLeX). These are terminal epitopes of glycan chains in proteins and glycolipids that play a decisive role in cancer cell hematogenous dissemination by interacting with E-selectin on activated endothelial cells[103].Moreover,they promote cancer cell adhesion to platelets through P-selectin and lymphocytes through L-selectin, which are critical aspects to support survival in circulation and evade immune responses [104]. There are many other examples of how glycans impact key cancer hallmarks, as elegantly highlighted by recent reviews [39,105].

    Figure 3 Zooming in on the sugar coating of cancer cells has provided the identification of glycoproteins holding potential for targeted therapiesSLeA, a terminal glycan epitope of glycolipids and membrane glycoproteins,is commonly overexpressed in gastric tumors and is an important ligand of E-selectin,playing a key role on E-selectinmediated disease dissemination. Exploring the SLeA proteome allows to increase specificity and overcome some expression associated with non-malignant conditions. NCL-SLeA, a wellknown mislocalized protein in cancer, has emerged as a topranked targetable glycoprotein at cell membrane in gastric cancer and a potential E-selectin ligand. Moreover, only the protein glycoform was associated with decreased overall survival,showing the added value of glycosylation for biomarker discovery. NCL,nucleolin; NCL-SLeA, nucleolin-sialyl-Lewis A glycoform;NCLmem, nucleolin expressed at the cell membrane.

    There are numerous studies associating STn, SLeA, and other glycoforms with worst prognosis and metastatic spread[106,107].Notably,STn and SLeAglycans are rarely expressed by healthy tissues, where they are confined to cells specialized in secretion across the lumen of the gastrointestinal and respiratory tracts as well as in secreted mucins, acting as a protective barrier against pathogens and contributing to immunological homeostasis [37,108]. These glycans are also not expressed in blood cells in circulation, standing as potential biomarkers[109,110].This has prompted their exploitation with relative success for targeted therapeutics and immunotherapy in pre-clinical and clinical settings, with emphasis on chimeric antigen receptor T (CAR-T) cells and cancer vaccines, as reviewed recently [111,112]. Namely,CAR-Ts designed against cancer cells expressing the Tn and STn antigens hold potential toward this objective, given their restricted expression pattern in healthy human tissues[111,113].On the other hand,glycan-based vaccines,while capable of inducing high antibody titters, have not been able to induce effective and long-lasting cellular immunity against tumors [114,115].

    To this date, the establishment of immunization strategies capable of overcoming the low immunogenicity and immunosuppressive nature of cancer-associated glycans remains an outstanding challenge. However, the concept of neoantigens does not apply to glycans alone, [116] with the only known exception coming from the incorporation of Nglycolylneuraminic acid (Neu5Gc; sialic acid) from dietary sources such as red meat, which induces the formation of xenoantigens in human glycan chains[117].Neoantigen signatures may be obtained from glycopeptides, granting bispecificity both via the glycan and the peptide chain[118,119].Supporting this hypothesis, glycoarray-based studies have identified autoantibodies against distinct mucin variable tandem repeat glycoproteoforms in the serum of cancer patients[120,121]. Autoantibodies showed cancer-specific recognition of targeted glycans, regardless of disease-associated variations in glycan density and distribution in peptide chains,supporting the existence of molecular fingerprints of disease that should be explored for cancer targeting. Accordingly, understanding the repertoire of glycans stands out as a decisive step for zooming in on the cancer glycoproteome. We have recently explored this approach to demonstrate the presence of unusual glycoproteins at the cell surface, such as the case of nucleolin(NCL)[122].NCL is mostly confined to the nucleus of healthy cells, but it may migrate to the cell surface where it appears glycosylated in different types of solid tumors [122–126](Figure 3).These are striking observations since NCL presents neither hydrophobic transmembrane domains nor a targeting signal to the cell membrane that could justify glycosylation[127]. The mechanisms governing this protein mislocalization remain to be fully elucidated; nevertheless, it becomes clear that this cancer-specific alteration presents enormous potential for precise targeting. Many similar examples have been reported in the literature, which set an important novel paradigm for biomarker research and can be comprehensively explored in the future [128–130].

    Figure 4 Glycomics and glycoproteomics conventional workflows for the identification of potential targetable glycobiomarkersA. Immobilization of extracted glycoproteins from biological material on PVDF membrane allows consecutive release of N-glycans and O-glycans by PNGase F digestion and reductive β-elimination,respectively.This protocol comprises analysis of the released and reduced glycans by PGC–nanoLC–ESI–MS/MS. B. An achievement for the field of (glyco)proteomics in the last years was the introduction of MALDI Imaging,which adds spatial information to molecular specificity provided by MS.The main steps of a MALDI-MSI protocol for protein and N-glycan analyses are very similar. After removal of paraffin in FFPE tissues, PNGase F or trypsin is applied on the tissue section, to release N-glycans from glycoproteins or obtain digested peptides, followed by application of MALDI matrix. Besides the average mass spectrum obtained for each tissue section, the distribution of the most abundant glycans or peptides can be visualized individually across the tissue. Moreover, identification of N-glycans and/or peptides can be confirmed by MS/MS on tissue extracts. For the sequential analysis of peptides on the same tissue section used previously for N-glycan analysis, an intermediate washing step to remove MALDI matrix,N-glycans,and PNGase F is necessary in addition to the antigen retrieval step.C.The information generated by glycomics experiments is pivotal for guiding glycoproteomics by employing a glycan-targeted proteomics approach. Therefore, this includes an initial enrichment of extracted cell membrane proteins for the glycan of interest, followed by separation of glycoproteins according to the molecular weight and analysis by nanoLC–MS/MS using a bottom-up approach. Combined bioinformatics tools are employed toward curated data, through comparison with transcriptomics data, protein expression data from healthy and tumor tissues,and evaluation of subcellular location. PVDF, polyvinylidene fluoride; PNGase F, peptide-N-glycosidase F; EIC, extracted ion chromatogram; PGC, porous graphitized carbon; LC, liquid chromatography; ESI, electrospray ionization; FFPE, formalin-fixed paraffin-embedded; α-CHCA, α-cyano-4-hydroxycinnamic acid; MALDI-MSI, matrix-assisted laser desorption/ionization mass spectrometry imaging; PNA, peanut agglutinin; VVA, Vicia villosa agglutinin; NeuAse, neuraminidase.

    When taking into account the relevance of integrating glycan information into protein surrogates, there are several examples on how considering cancer-associated glycoforms of classical biomarkers has improved their clinical value(PSA,MUC16,CEA,and CD133)[86,90,131–133].Moreover,focusing on glycans on HER2, PD-1, and PD-L1 has allowed to provide important footprints for patient stratification, better predict treatment response, and improve the efficacy of therapeutic antibodies [102,134–139]. In summary, glycosylation provides functional and microenvironmental contexts to cell membrane proteins, and targeting glycosylated moieties may lead to previously unforeseen glycoproteomics signatures at the cell surface, paving the way toward disease-specific glycoproteoforms.

    Glycomics and glycoproteomics:concepts,strategies,and challenges facing biomarker discovery

    The comprehensive combination of glycomics and glycoproteomics will be crucial toward the identification of novel cancer biomarkers of clinical value, with emphasis on unforeseen cancer-specific signatures reflecting molecular alterations at the genome, transcriptome,proteome,and metabolome levels.Glycomics addresses the repertoire of glycans in a biological system and is a critical milestone for identification of glyconeoantigens.MS is by far the most widely used analytical tool in a field that has been progressing fast,backed by the increasing sensitivity and resolution of mass spectrometers [140,141].Moreover, important steps have been made toward protocol standardization [142], automatization [143], and bioinformatics [144], setting the foundations for carbohydrate metrology.However, despite intense research and robust proofs of concept, the implementation of MS-based glycome signatures in clinical practice has yet to be established and poses significant analytical, clinical, and regulatory difficulties, namely the lack of well-defined glycan standards as well as biased reproducibility resulting from a wide array of MS architectures. Notably,lectin microarrays of variable architectures have been proposed as high-throughput alternative technologies, which may be particularly important in the context of liquid biopsies,but of limited use for glycoantigen discovery [145]. Facing mature technology, the field should now push toward a comprehensive, large-scale interrogation of the human glycome.This will decisively prompt our understanding of glycan diversity in health and disease, including the foundations to assertively tackle the glycoproteome.

    Glycomics

    Glycan analysis poses a significant analytical challenge due to its non-templated and structural heterogeneity and frequent co-existence of isomeric/isobaric structures in the same sample[146,147]. MS remains the gold standard technique, but support from nuclear magnetic resonance(NMR),complementary enzymatic methods, and immunoassays may be required for more detailed structural elucidation. Typical protocols initiate with the selective release of glycans from glycoproteins by either enzymatic or chemical methods. N-glycans are isolated by peptide-N-glycosidase F (PNGase F) or PNGase A digestion, whereas O-GalNAc glycans are obtained by reductive β-elimination through chemical methods [148].

    Focusing on N-glycans,PNGase F digestion has the advantage of tagging substituted Asn residues in protein chains,facilitating downstream glycosite identification by glycoproteomics [149]. This can be achieved in proteins in solutions,immobilized in polyacrylamide gels, and even in tumor sections [150–152]. However, the immobilization of purified glycoproteins or protein mixtures on polyvinylidene fluoride(PVDF) membranes prior to enzymatic and chemical treatments significantly facilitates glycan release from minute amounts of biological material (nano-femtomole) [153](Figure 4A).Notably,PNGase F works well for glycoproteins,whereas PNGase A is more recommended for deglycosylation of glycopeptides [154,155]. Moreover, PNGase A differs from PNGase F in the fact that it is able to cleave N-linked glycans with or without α(1,3)-linked core fucose residues, whereas PNGase F is incapable of cleaving glycans showing this particular structural feature [156]. Glycans may then be directly analyzed by MS in their native form, providing an overview on the main classes of available structures. Alternatively, they may be resolved by LC into isomeric structures,as advocated by glycomics consensus guidelines [157]. The upfront identification of regioisomers may be accomplished by LC–MS/MS using different types of columns [hydrophilic interaction (HILIC) [158], zwitterionic interaction, porous graphitized carbon (PGC) [159], or C4-C18 reverse phase[160]]. However, complementary sample treatment with sialidases and other specific exoglycosidases may be necessary for more detailed structural characterization of complex stereoisomers. A promising approach to overcome this limitation is to include ion mobility spectrometry (IMS) as an additional gas-phase separation dimension, which will probably constitute routine in a near future[161].Glycans may be derivatized prior to analysis to facilitate chromatography and improve ionization properties. The most popular, well-established,and widely applied derivatization method is permethylation,allowing to address both N- and O-glycans at an omics scale.Permethylation stabilizes labile sugars such as fucose and sialic acids, preventing fucose migration and enabling detection by soft ionization methods, such as matrix-assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI)[162,163]. Moreover, it renders glycans more hydrophobic,thus facilitating separation by conventional C18 reverse phase LC columns and positive ionization by both MALDI and ESI,and improving sensitivity. Another popular derivatization approach for N-glycans comprehends reductive amination,which resorts to labels such as 2-aminobenzamide or 2-aminobenzoic acid, allowing fluorescence detection and quantification [164]. The introduction of fluorescent tags has also permitted the construction of MS-independent platforms for rapid N-glycomics, crucial for the generalization of glycomics analysis at a wider scale. Other less explored approaches for quantitative analysis of N-glycans include isobaric tags,such as aminoxyTMT[165]and QUANTITY[166].These tags can be conjugated with the reducing end of N-glycans,allowing their quantification by LC–MS using report ions.Currently,underivatized glycan analysis has been gaining ground with the introduction of PGC–LC columns that allow a good separation of isomeric structures. Moreover, important steps have been made toward standardization, with the recent establishment of PGC–LC–MS N-glycan retention libraries and elution mapping resources [167]. While the field evolves toward less time-consuming PGC platforms, permethylation still remains by far the most used derivatization method for glycan analysis at the micromolar scale. In addition, product ion spectra of permethylated glycans are greatly informative by providing ions derived from both glycosidic linkages and cross-ring fragmentations [168,169], and several libraries exist for the interpretation of LC chromatograms[160,170].

    Analysis of O-glycans has been particularly challenging due to the lack of enzymatic approaches. In fact, until recently O-glycosidase was the only available enzyme to address this objective. However, this enzyme catalyzes the removal of core 1 and core 3 O-linked disaccharides from glycoproteins but does not act on more elongated O-glycans that are commonly found in human cell glycome[171].Notably,O-proteases,such as StcE (acting on mucins) and OpeRATOR, have been recently introduced for studying O-glycopeptides [172,173],holding true potential to improve sequence coverage,glycosite mapping, and glycoform analysis. Accordingly, O-glycomics analysis still relies on chemical methods that often degrade the protein backbone and thus significantly reduce the sensitivity of analysis. However, addition of a reducing agent in the most widely employed O-glycan release strategy, reductive β-elimination, prevents the glycan degradation resulting from‘‘peeling reactions”. The limitation of lacking enzymatic approaches has been recently addressed by the introduction of a semi-quantitative method that exploits a mimetic of the Tn antigen (benzyl-GalNAc) as a scaffold to determine the structure of more extended glycan chains[174,175].Moreover,it increased sensitivity of analysis by 100–1000 folds when compared to chemical methods and identified a more complex repertoire of O-glycans [174]. However, while extremely elegant,this technique is limited to cell culture-based approaches,being unsuited to support studies in vivo or ex vivo. In addition,many new tools have been introduced in the recent years to overcome several limitations associated with the analysis and quantification of both N- and O-glycans. For example,solid-phase chemoenzymatic approaches have been proposed to improve N-and O-glycomics[176–178]and several chemical methods have been introduced for easy identification of different types of sialic acid linkages in glycan chains (α2,3, α2,6,α2,8, or α2,9) [179], which are decisive for defining functional traits.Overall,MS has paved the way for functional glycomics and glycobiomarker discovery. In this context, another major achievement was the introduction of MS imaging, which enables analysis in situ using fresh but also formalin-fixed embedded tissues with high sensitivity [180,181]. The generalization of this approach confers spatial resolution to glycomics and glycoproteomics studies and paves the way for more robust and context-customized glycoproteomics (Figure 4B).Collectively, the field has reached the maturity to support large-scale multiomics studies.

    Glycoproteomics

    The bulk of genetic and epigenetic alterations in protein glycosylation pathways occurring in cancer cells are reflected on the cell surface [182,183]. These include changes not only in the structure, length, and charge of glycan chains but also in the abundance and occupancy of glycosites in a protein, which decisively shape protein functions and concomitantly provide molecular signatures for targeted therapeutics and immunotherapy[39,91,184].Providing information on the nature and abundance of glycosylated proteins, as well as on the distribution and composition of glycosites for a given biological milieu, has been the subject of glycoproteomics. Nevertheless,cell membrane glycoproteins constitute a small portion of the proteome[185].A sample pre-enrichment for the glycans of interest, guided by a prior knowledge of the glycome, is often elected as the starting point to overcome this limitation[90,122]. Samples may be pre-enriched for species of interest by physical methods, immunoprecipitation, and affinity chromatography targeting specific glycans with antibodies or lectins, prior to analysis by MS [80,122,186]. Digestions with glycosidases may also be introduced to generate desired glycostructures for lectin affinity chromatography prior to MS analysis.As a typical example,many studies addressing glycoproteins carrying short-chain STn antigens in cancer employ sialidases to generate the Tn antigen,enabling enrichment with the Vicia villosa agglutinin (VVA) lectin [90]. A similar rationale has been used to enrich samples for proteins carrying ST antigens using the peanut agglutinin (PNA) lectin [187](Figure 4C). Building on these protocols, in the last decade,Vakhrushev et al. [80] developed an elegant strategy for high-throughput identification of O-GalNAc glycosites by exploiting genome editing technologies. This strategy is based on knockout of COSMC (C1GALT1-specific chaperone),which restricts O-glycosylation to the simplest Tn and STn antigens suitable for VVA enrichment [80,186]. This simplification of cell glycosylation has allowed to overcome O-glycosylation heterogeneity, facilitating MS/MS-based glycopeptide identification, which significantly contributes to expanding current knowledge of human O-glycoproteome[80,186].

    MS coupled to LC using nano-flow stands as the gold standard technique for glycoprotein annotation from minute amounts of starting material [188].The development of highly sensitive and accurate mass spectrometer analyzers enabled deep proteome mining, providing the identification and quantification of a vast array of proteins and peptides while simultaneously informing on their PTMs [141]. Currently, standard ionization methods for protein and PTM analyses involve MALDI and nano-ESI. Additionally, the employment of hybrid mass analyzers, such as quadrupole time-of-flight(QTOF),time-of-flight/time-of-flight(TOF/TOF),ion trap/orbitrap (IT/Orbitrap), and quadrupole/orbitrap (Q/Orbitrap),which allow MS/MS experiments, has contributed to increasing confidence in protein identification and accurate mapping of PTM sites[76].Moreover,the new generation of mass spectrometers with a tribrid architecture,namely combining quadrupole, linear ion trap, and orbitrap mass analyzers, will enhance protein coverage, improve fragmentation, and provide more comprehensive identification and characterization of proteomes [189].

    Figure 5 Onco-glycoproteogenomics toward safer and more effective immunotherapy and precision oncologyThe comprehensive combination of the different omics is crucial for discovery of unforeseen tumor unique molecular signatures.Moreover, it will allow a thorough understanding of microenvironmental and functional contexts of glycoproteoforms, toward the rational design of targeted therapeutics.

    Protein and PTM identification by MS can be achieved by different strategies.The most widely used approach consists in a bottom-up analysis of peptides derived from the digestion of proteins with different proteases by nanoLC–MS/MS. Conventionally, C18 reverse phase columns have been shown to be sufficiently versatile for chromatography prior to MS[190].However,HILIC chromatography enables good separation of glycopeptides from protein mixtures,as well as efficient separation between neutral and sialoglycopeptides, while allowing more efficient structural characterization, mainly in the presence of a neutral or zwitterionic stationary phase[191,192]. Noteworthily, glycosylation often renders proteins less prone to proteases, limiting the success of these approaches [193]. As such, many studies combine different broad-spectrum proteolytic enzymes to increase protein coverage and the chances of glycopeptide identification. Alternatively, the middle-down approach enables the analysis of large peptides resulting from mild proteolysis [194]. Finally,top-down analysis contemplates the identification of intact protein mass by MS followed by direct ion dissociation in the gas phase [195]. Relative and absolute quantification of proteins and PTMs has been classically achieved by 2-DE, before MS-based approaches emerged [196]. MS-based methods involve stable isotopic metabolic labeling[stable isotope labeling by amino acids in cell culture (SILAC) and stable isotope labeling with amino acids in mammal (SILAM)] and postmetabolic labeling [isobaric tags for relative and absolute quantification (iTRAQ), tandem mass tag (TMT), and isotope-coded affinity tag (ICAT)] [197]. However, with the increased resolution and sensitivity of modern mass spectrometers,label-free quantification(LFQ)methods have been gaining ground. These methods generally include the computational analysis of MS ion intensity,spectral counting,chromatogram peak area determination, or targeted approaches, such as selected reaction monitoring (SRM)[197].MS/MS,with different fragmentation methods,provides more structural information, such as glycosites. Collisioninduced dissociation (CID) is the most used and easily available ion fragmentation methodology. It consists in the collision of selected molecular ions with an inert gas (argon,nitrogen, or helium), leading to the fragmentation of protonated amide linkages, while frequently favoring neutral loss of glycan moieties[198].Although capable of providing significant information on peptide sequence, CID does not provide ideal diagnostic ion information for the identification of glycopeptides. Contrastingly, electron capture dissociation(ECD) induces preferential cleavage of peptide backbones at the N-Cα bond, preventing the glycan-associated neutral loss,and thus being a better approach for glycopeptide identification [199]. More recently, electron transfer dissociation(ETD) was developed, showing many similarities with ECD;however, it can be performed in ion trap mass spectrometers or even in QTOF type instruments [200]. Moreover, highenergy collision dissociation (HCD) was implemented essentially in orbitrap platforms. Although similar to CID, in HCD, fragmentation is carried at higher collision energies,ensuring accurate glycopeptide diagnosis through the generation of typical glycan oxonium ions [201]. Lastly, electrontransfer/higher-energy collision dissociation (EThcD) is a hybrid dissociation method, resulting from combination of ETD and HCD. It provides higher peptide sequence coverage by simultaneously providing HCD diagnostic glycan ions and ETD-derived peptide fragments with preserved information on modification sites, facilitating PTM site assignment [202].Namely, it has shown promising results for glycoproteomics analysis by providing both glycan and peptide fragment spectral information through cleavage of amide and glycosidic linkages [203]. Regardless of the methodological approach selected for protein identification, there is still a gap between protein identification and biomarker discovery. In silico approaches have revealed more accurate assignments and identified relevant glycobiomarkers for clinical translation [204].This strategy encompasses several bioinformatics tools to validate protein identification (SequestHT, Proteome Discoverer,and SwissProt database), glycosylation sites (NetNGlyc and NetOGlyc), biological functions (Panther, STRING, Cytoscape, and UniProtKB), and associations to histological data(Oncomine and The Human Protein Atlas) [204] (Figure 4C).Recently, a novel in silico prediction approach for mucintype O-GalNAcylation termed ISOGlyP (https://isoglyp.utep.edu/) has also been introduced to assist the identification of potential glycoproteins [205]. Moreover, Byonic software has emerged as a powerful tool toward automated identification of glycopeptide mass spectra,at level of glycosite modification.It allows the use of a generic glycan list, composed by a wide array of N- and O-glycan structures, or a customized list for search and identification of modified peptides. Nevertheless,it still requires manual validation [81,82]. In summary, given the large panoply of methodological approaches,it is now possible to personalize workflows toward more accurate access to cellular and tissue glycome and glycoproteome, ultimately facilitating clinical translation.

    Glycoproteogenomics: a new concept in the crossroad between nucleic acids, proteins, and carbohydrates

    The full characterization of the glycoproteome remains a daunting analytical enterprise whose success is directly linked to the level of understanding about the nature of proteoforms and glycoforms.The array of proteoforms available for glycosylation is dependent on the genome and the subsequent events that culminate in protein synthesis and maturation[35].On the other hand, glycosylation is not a direct gene product, but rather the result of a highly regulated process mediated by a wide array of glycosyltransferases, glycosidases, chaperones,and sugar donors along protein secretory pathways [39]. As such,not a single omics can accurately predict glycoproteome,making it necessary to adapt conventional strategies to accommodate molecular information of distinct origins. This has been, to some extent, partially minimized by shaping conventional proteomics workflows to accommodate the presence of glycans. However, significant amounts of glycoproteomics data generated by nanoLC–MS/MS runs remain undeciphered due to the lack of genome-customized protein databases used for protein annotation.

    Glycoproteogenomics is a rather novel concept that attempts to bridge genes, proteins, and PTMs to bring new awareness to protein functions and ultimately provide targetable protein nodes (Figure 5). To our knowledge, the concept was first explored by Rolland et al. [42] in 2017, by integrating N-glycoproteomics and transcriptome sequencing to identify relevant signaling networks and therapeutic targets in lymphomas.In the following year,Mun et al.[41]combined mRNA,protein,phosphorylation,and N-glycosylation data to identify different subtypes of diffuse gastric cancer in young populations. PTMs are particularly important for defining subtypes associated with immune- and invasion-related pathways. However, the term glycoproteogenomics was only formally introduced by Lin et al. [206] in a study concerning human serum α-2-HS-glycoprotein. The authors have demonstrated correlations between gene polymorphisms and changes in glycosylation for this protein [206]. A wide variability of proteoforms was also observed, suggesting need for quantitative profiling to foresee improved biomarkers for different disease states. Taken together, these studies elegantly highlight the pivotal role played by glycans in human biology and the importance of associating different omics for improved cancer biomarkers. However, it remains crucial to progress beyond incrementality toward more integrated and interconnected approaches.

    In a broader sense, we conceptualize that glycoproteogenomics addresses the protein species resulting from a wide array of events,including gene polymorphisms and mutations,differential transcription, and glycosylation occurring in biological milieus.These events generate a wide number of glycoproteoforms for the same protein, which require integrated analytical workflows for comprehensive characterization. Proteogenomics has led the way by providing the conceptual framework to accomplish this goal. Adapting current approaches to accommodate the structural diversity of glycans and the physicochemical subtleties introduced by glycosylation in proteins will be the next logical step toward glycoproteogenomics. We anticipate that genomics and glycomicscustomized protein identification methods will be crucial for understanding the role of glycoproteins in cancer. The identification of unforeseen molecular signatures is plausible to pave the way for neoantigen discovery and novel therapeutics.

    CRediT author statement

    Jose′ Alexandre Ferreira: Conceptualization, Methodology,Software,Data curation,Writing-original draft,Supervision,Project administration, Funding acquisition. Marta Relvas-Santos:Methodology,Software,Data curation,Writing-original draft, Visualization. Andreia Peixoto: Writing - review &editing. Andre′ M.N. Silva: Software, Resources, Writing -review & editing, Supervision. Lu′cio Lara Santos: Resources,Writing - review & editing, Supervision, Project administration, Funding acquisition. All authors read and approved the final manuscript.

    Competing interests

    The authors have declared no competing interests.

    Concluding remarks

    Novel sources of cancer neoantigens are urgently needed to address cold tumors,showing low mutational frequencies,lack of T cell infiltration, and poor response to current immune checkpoint inhibitors. Glycans are essential components of biological systems that hold enormous potential toward this end,since they are present at the cell surface and can be easily targeted by ligands of different natures,including lectins of the immune system. Nevertheless, they are often neglected in the context of biomarker research facing the enormous amount of information on the cancer genome,transcriptome,and proteome. The technological readiness of high-throughput genomics and proteomics platforms has not only prompted cancer neoantigen discovery but also led to the generation of effective cancer vaccines. Moreover, genomics, transcriptomics, and more recently, proteogenomics have improved the molecular subtyping of human tumors and currently constitute a paramount framework toward precision oncology.Nevertheless,zooming in on the glycoproteome of cancer cells backed by a profound understanding about the cancer glycome may provide yet unforeseen molecular signatures,constituting another crucial milestone toward systems biology.However, mapping of the glycoproteome cannot be achieved without bridging different sources of information. It becomes imperative to systematize procedures to bring together genomics and transcriptomics information, enabling the accurate customization of proteomics databases with the integration of cancer-specific gene polymorphisms and alternative splicing transcripts. It is also mandatory to integrate PTMs that decisively define molecular functions. In this sense, glycosylation holds tremendous potential, as it provides well-known glycan cancer signatures and confers functional and metabolic contexts to the membrane proteome. Furthermore, setting the aim in cancer glycoproteogenomics-derived peptide identification will provide bispecific neoantigens. This wish list comes with outstanding computational challenges,aiming at integrating and extracting information from multiple layers of data.Nevertheless, it will undoubtedly unveil novel and even unexpected molecular signatures, providing a more thorough understanding of biological systems, improved tumor classification capacity, and a more rational design of personalized cancer therapies.

    Acknowledgments

    The authors wish to acknowledge the Portuguese Foundation for Science and Technology (FCT) for the PhD grants (Grant Nos. SFRH/BD/111242/2015 awarded to AP and SFRH/BD/146500/2019 awarded to MRS)and the FCT assistant researcher grant (Grant No. CEECIND/03186/2017 awarded to JAF).FCT is co-financed by European Social Fund(ESF)under Human Potential Operation Programme(POPH)from National Strategic Reference Framework (NSRF). The authors also acknowledge the FCT funding for CI-IPOP research unit (Grant No. PEst-OE/SAU/UI0776/201) and LAQV-REQUIMTEresearchunit(GrantNo.UIDB/50006/2020), the Portuguese Oncology Institute of Porto Research Centre (Grant Nos. CI-IPOP-29-2020,CI-IPOP-58-2020, and CI-IPOP-Proj.70-bolsa2019-GPTE),and the PhD Program in Biomedical Sciences of ICBAS-University of Porto in Portugal. The authors also thank the ‘‘Early stage cancer treatment, driven by context of molecular imaging (ESTIMA)” framework (Grant No.NORTE-01-0145-FEDER-000027) and the IPO-Score (Grant No. DSAIPA/DS/0042/2018) for financial support. This work was financed by European Regional Development Fund(ERDF) through the COMPETE 2020 – Operational Programme for Competitiveness and Internationalisation(POCI),Portugal 2020, and by Portuguese funds through FCT / Ministry for Science,Technology and Higher Education(MCTES).

    ORCID

    0000-0002-0097-6148 (Jose′ Alexandre Ferreira)

    0000-0001-5764-5414 (Marta Relvas-Santos)

    0000-0001-9514-0775 (Andreia Peixoto)

    0000-0001-5554-7714 (Andre′ M.N. Silva)

    0000-0002-0521-5655 (Lu′cio Lara Santos)

    26uuu在线亚洲综合色| 精品久久久久久久末码| 好男人视频免费观看在线| 亚洲欧美一区二区三区国产| 极品教师在线视频| 一个人免费看片子| 日韩视频在线欧美| 九草在线视频观看| 国产熟女欧美一区二区| 国产精品一区二区性色av| 成人毛片60女人毛片免费| 少妇丰满av| 亚洲欧洲日产国产| 91久久精品国产一区二区成人| 亚洲四区av| 极品教师在线视频| 午夜免费观看性视频| 亚洲成人av在线免费| 天天躁夜夜躁狠狠久久av| 久久精品国产自在天天线| 国产亚洲最大av| 99久久精品国产国产毛片| 蜜桃久久精品国产亚洲av| 91狼人影院| 中文字幕av成人在线电影| 丰满人妻一区二区三区视频av| 91在线精品国自产拍蜜月| 日韩 亚洲 欧美在线| 一个人免费看片子| 熟女电影av网| 精品久久久久久久久亚洲| 成人影院久久| 大香蕉97超碰在线| 直男gayav资源| 亚洲在久久综合| 亚洲精品亚洲一区二区| 国产成人精品婷婷| 能在线免费看毛片的网站| 久热久热在线精品观看| 国产成人午夜福利电影在线观看| 三级国产精品欧美在线观看| 少妇人妻久久综合中文| 亚洲欧美日韩卡通动漫| 日本黄色片子视频| 国产av一区二区精品久久 | 久久精品人妻少妇| 18禁在线无遮挡免费观看视频| 欧美成人a在线观看| 国产无遮挡羞羞视频在线观看| 久久久精品免费免费高清| 亚洲电影在线观看av| 日韩精品有码人妻一区| 天美传媒精品一区二区| 三级国产精品片| 80岁老熟妇乱子伦牲交| 制服丝袜香蕉在线| 99热网站在线观看| 欧美日韩视频高清一区二区三区二| 99九九线精品视频在线观看视频| 日本一二三区视频观看| 直男gayav资源| 国产在线免费精品| 国产 一区精品| 国产精品爽爽va在线观看网站| 国内精品宾馆在线| 99久久人妻综合| www.av在线官网国产| 亚洲欧美精品专区久久| 91久久精品国产一区二区三区| 精品一区二区三区视频在线| 国产色爽女视频免费观看| 国产精品一区二区在线观看99| 美女主播在线视频| 一级毛片久久久久久久久女| 国产乱来视频区| 日韩欧美一区视频在线观看 | 国产 一区精品| 一级二级三级毛片免费看| 最近的中文字幕免费完整| 精品一品国产午夜福利视频| 亚洲av中文字字幕乱码综合| 精品国产一区二区三区久久久樱花 | 日本欧美视频一区| 亚洲成人av在线免费| 精品久久久久久电影网| 美女福利国产在线 | 九九在线视频观看精品| 九九久久精品国产亚洲av麻豆| 久久 成人 亚洲| 狠狠精品人妻久久久久久综合| 国产一区二区三区综合在线观看 | 久久国内精品自在自线图片| 中文在线观看免费www的网站| 欧美最新免费一区二区三区| 草草在线视频免费看| 国产成人免费无遮挡视频| 欧美成人精品欧美一级黄| 十八禁网站网址无遮挡 | 九色成人免费人妻av| 国产老妇伦熟女老妇高清| 国产成人a区在线观看| av天堂中文字幕网| 精品一区二区免费观看| 嫩草影院入口| 亚洲av在线观看美女高潮| 波野结衣二区三区在线| 色婷婷av一区二区三区视频| 国产免费一区二区三区四区乱码| 亚洲精品一区蜜桃| .国产精品久久| 亚洲怡红院男人天堂| 六月丁香七月| 伊人久久国产一区二区| 精品国产露脸久久av麻豆| 我的女老师完整版在线观看| 日本一二三区视频观看| 亚洲第一av免费看| 边亲边吃奶的免费视频| 国产精品三级大全| 水蜜桃什么品种好| 另类亚洲欧美激情| 日日啪夜夜撸| 国产精品精品国产色婷婷| 色视频www国产| 亚洲在久久综合| 亚洲成人中文字幕在线播放| 国产黄片视频在线免费观看| 国产v大片淫在线免费观看| 内射极品少妇av片p| 国产 一区精品| 免费观看性生交大片5| 在线亚洲精品国产二区图片欧美 | 晚上一个人看的免费电影| 亚洲国产日韩一区二区| 少妇丰满av| 久久久国产一区二区| 亚洲婷婷狠狠爱综合网| 亚洲精品456在线播放app| 久久久久久久亚洲中文字幕| 边亲边吃奶的免费视频| 欧美另类一区| 国产乱来视频区| 人人妻人人爽人人添夜夜欢视频 | 在线观看免费日韩欧美大片 | 在线观看一区二区三区| 国产成人a∨麻豆精品| 精华霜和精华液先用哪个| 成人影院久久| 麻豆精品久久久久久蜜桃| 一个人看视频在线观看www免费| 成人黄色视频免费在线看| 亚洲欧美日韩卡通动漫| 亚洲精品乱码久久久v下载方式| 99精国产麻豆久久婷婷| 最近最新中文字幕免费大全7| 99久久精品国产国产毛片| 欧美97在线视频| 男女边摸边吃奶| 欧美一区二区亚洲| 国产欧美日韩一区二区三区在线 | 欧美xxⅹ黑人| 黑人高潮一二区| 国产人妻一区二区三区在| 国产日韩欧美在线精品| 精品国产露脸久久av麻豆| 久久久久久伊人网av| 婷婷色综合www| 男人添女人高潮全过程视频| 亚洲av中文av极速乱| 国产综合精华液| 亚洲美女搞黄在线观看| 肉色欧美久久久久久久蜜桃| 日韩中文字幕视频在线看片 | 看免费成人av毛片| 日本-黄色视频高清免费观看| 爱豆传媒免费全集在线观看| 国产成人aa在线观看| 尾随美女入室| 在线观看一区二区三区| 亚洲欧美清纯卡通| 国产成人精品一,二区| 午夜福利高清视频| 成人18禁高潮啪啪吃奶动态图 | 七月丁香在线播放| 亚洲国产精品成人久久小说| 欧美老熟妇乱子伦牲交| 日本午夜av视频| 精品久久久精品久久久| 国产免费又黄又爽又色| 亚洲精品久久久久久婷婷小说| 人人妻人人添人人爽欧美一区卜 | 国内少妇人妻偷人精品xxx网站| 一级毛片电影观看| 国产v大片淫在线免费观看| 久久女婷五月综合色啪小说| av又黄又爽大尺度在线免费看| 97精品久久久久久久久久精品| 亚洲,欧美,日韩| 亚洲怡红院男人天堂| 久久久色成人| 日韩成人伦理影院| 成人国产麻豆网| 大香蕉97超碰在线| 久久毛片免费看一区二区三区| 欧美精品一区二区免费开放| 18禁在线无遮挡免费观看视频| 中文字幕久久专区| 久久99蜜桃精品久久| 六月丁香七月| 免费人成在线观看视频色| 国产黄频视频在线观看| 嫩草影院入口| 男人添女人高潮全过程视频| 亚洲精品,欧美精品| 在线观看免费高清a一片| 精品久久久噜噜| 日产精品乱码卡一卡2卡三| 午夜福利视频精品| 夜夜爽夜夜爽视频| 一区二区三区精品91| 王馨瑶露胸无遮挡在线观看| 一级毛片aaaaaa免费看小| 久久99蜜桃精品久久| 亚洲高清免费不卡视频| 男女无遮挡免费网站观看| 久久99精品国语久久久| 欧美成人一区二区免费高清观看| 联通29元200g的流量卡| 国产精品无大码| 欧美xxxx黑人xx丫x性爽| 在线观看免费视频网站a站| 久久国产乱子免费精品| 亚洲国产最新在线播放| 小蜜桃在线观看免费完整版高清| 日韩中字成人| 久久久色成人| 亚洲久久久国产精品| 久久久久久久久大av| 最近的中文字幕免费完整| 少妇高潮的动态图| 在线观看三级黄色| 国产视频内射| 色网站视频免费| a级毛片免费高清观看在线播放| 亚洲av不卡在线观看| 午夜福利在线观看免费完整高清在| 亚洲av电影在线观看一区二区三区| 久久精品国产a三级三级三级| 国产永久视频网站| 91久久精品国产一区二区成人| 精品久久久噜噜| 精品人妻视频免费看| 我要看黄色一级片免费的| 日韩成人伦理影院| 高清日韩中文字幕在线| 韩国av在线不卡| av福利片在线观看| 国国产精品蜜臀av免费| 99热这里只有精品一区| 国产永久视频网站| 男男h啪啪无遮挡| 秋霞伦理黄片| 男女下面进入的视频免费午夜| 下体分泌物呈黄色| 色综合色国产| 国产亚洲午夜精品一区二区久久| 国产精品久久久久久久久免| 亚洲电影在线观看av| 欧美一区二区亚洲| 亚洲人成网站高清观看| 欧美日韩在线观看h| 国产精品久久久久成人av| 人人妻人人爽人人添夜夜欢视频 | 久久精品久久久久久噜噜老黄| 丝袜脚勾引网站| 亚洲色图av天堂| 国产精品欧美亚洲77777| 亚洲美女搞黄在线观看| 中文字幕av成人在线电影| av卡一久久| 80岁老熟妇乱子伦牲交| 99久久精品热视频| 国产中年淑女户外野战色| 人人妻人人澡人人爽人人夜夜| 免费av中文字幕在线| 伊人久久国产一区二区| 国产精品偷伦视频观看了| 最近手机中文字幕大全| 人人妻人人爽人人添夜夜欢视频 | 视频区图区小说| 精品人妻熟女av久视频| 黄色日韩在线| 国产精品精品国产色婷婷| av在线老鸭窝| 美女主播在线视频| 久久久久精品性色| 国产白丝娇喘喷水9色精品| 伦理电影免费视频| videos熟女内射| 黄片无遮挡物在线观看| 大香蕉97超碰在线| 久久鲁丝午夜福利片| 精品久久国产蜜桃| 亚洲国产精品国产精品| av在线观看视频网站免费| 高清日韩中文字幕在线| 狂野欧美白嫩少妇大欣赏| 国产高清不卡午夜福利| 18禁在线播放成人免费| 久久久a久久爽久久v久久| 日本av免费视频播放| 亚洲国产色片| h日本视频在线播放| 国产精品爽爽va在线观看网站| 精品亚洲成国产av| 五月伊人婷婷丁香| 水蜜桃什么品种好| 插逼视频在线观看| 人人妻人人添人人爽欧美一区卜 | 亚洲真实伦在线观看| 久久韩国三级中文字幕| 在线观看一区二区三区激情| 深夜a级毛片| 国产 精品1| 99精国产麻豆久久婷婷| 久久久久久久精品精品| 午夜免费观看性视频| 亚洲国产精品专区欧美| 热re99久久精品国产66热6| 纵有疾风起免费观看全集完整版| 91久久精品国产一区二区成人| 国产精品人妻久久久久久| 777米奇影视久久| 成年av动漫网址| 欧美亚洲 丝袜 人妻 在线| 一本一本综合久久| 亚洲中文av在线| 亚洲av电影在线观看一区二区三区| 精品久久久噜噜| 亚洲美女视频黄频| 麻豆精品久久久久久蜜桃| av在线蜜桃| 国模一区二区三区四区视频| 日韩国内少妇激情av| 激情五月婷婷亚洲| 少妇精品久久久久久久| 欧美日韩精品成人综合77777| 少妇 在线观看| 寂寞人妻少妇视频99o| 欧美成人a在线观看| 亚洲久久久国产精品| 黑人猛操日本美女一级片| av在线老鸭窝| 日韩不卡一区二区三区视频在线| 久久精品久久久久久久性| 欧美精品人与动牲交sv欧美| 一本久久精品| 九草在线视频观看| 激情 狠狠 欧美| 日韩电影二区| 亚洲一级一片aⅴ在线观看| 精品99又大又爽又粗少妇毛片| 一区二区三区精品91| 国产精品久久久久久精品电影小说 | 欧美日韩视频精品一区| 国产成人aa在线观看| 天堂中文最新版在线下载| 亚洲婷婷狠狠爱综合网| 亚洲欧美日韩东京热| 舔av片在线| 成年女人在线观看亚洲视频| 国产精品一及| 蜜桃久久精品国产亚洲av| 中文欧美无线码| 少妇人妻精品综合一区二区| 永久网站在线| 亚洲综合精品二区| 精品酒店卫生间| 色视频在线一区二区三区| 亚洲精华国产精华液的使用体验| 爱豆传媒免费全集在线观看| 丝瓜视频免费看黄片| av国产免费在线观看| 成年免费大片在线观看| 在线观看av片永久免费下载| 国产精品熟女久久久久浪| 色网站视频免费| 午夜福利视频精品| 国产精品99久久久久久久久| 久久久久人妻精品一区果冻| 一级毛片aaaaaa免费看小| 国产一区亚洲一区在线观看| 99久久人妻综合| 久久精品久久久久久噜噜老黄| 妹子高潮喷水视频| 亚洲精品久久久久久婷婷小说| 欧美精品亚洲一区二区| 我的老师免费观看完整版| 最近手机中文字幕大全| 成人免费观看视频高清| av国产精品久久久久影院| 欧美+日韩+精品| 国产高清国产精品国产三级 | 亚州av有码| 新久久久久国产一级毛片| 亚洲成人中文字幕在线播放| 天堂俺去俺来也www色官网| 亚洲一区二区三区欧美精品| 亚洲人与动物交配视频| 成人毛片a级毛片在线播放| 亚洲四区av| 国产熟女欧美一区二区| 成人无遮挡网站| 波野结衣二区三区在线| 高清不卡的av网站| 日韩国内少妇激情av| 视频中文字幕在线观看| 久久av网站| 国产精品一区二区在线不卡| 国产成人午夜福利电影在线观看| 多毛熟女@视频| 国产欧美日韩精品一区二区| 午夜激情久久久久久久| 精品久久久噜噜| 精品午夜福利在线看| 最近最新中文字幕大全电影3| 国产精品一及| 精品亚洲成国产av| 国产精品一及| 精品亚洲成a人片在线观看 | 久久久a久久爽久久v久久| 一区二区av电影网| 直男gayav资源| 久久99热这里只有精品18| 国产爽快片一区二区三区| 国产一区二区在线观看日韩| 香蕉精品网在线| 亚洲熟女精品中文字幕| 男人狂女人下面高潮的视频| 91aial.com中文字幕在线观看| 少妇 在线观看| 婷婷色麻豆天堂久久| 99热6这里只有精品| 日日啪夜夜撸| 日韩一区二区三区影片| 婷婷色麻豆天堂久久| 国产乱来视频区| 国产黄频视频在线观看| 色视频www国产| 中文欧美无线码| 成人二区视频| 久久国产乱子免费精品| 女的被弄到高潮叫床怎么办| 国产一区二区在线观看日韩| 国产爽快片一区二区三区| 日本wwww免费看| 精品亚洲乱码少妇综合久久| 国产成人91sexporn| 老师上课跳d突然被开到最大视频| av在线老鸭窝| 视频区图区小说| 直男gayav资源| 亚洲综合色惰| av在线老鸭窝| 国产成人精品婷婷| 精品一品国产午夜福利视频| 国产精品欧美亚洲77777| 在线观看免费视频网站a站| 免费av中文字幕在线| 欧美高清成人免费视频www| 成人18禁高潮啪啪吃奶动态图 | 国产成人a∨麻豆精品| .国产精品久久| 日韩免费高清中文字幕av| 午夜福利在线观看免费完整高清在| 亚洲精品中文字幕在线视频 | 婷婷色麻豆天堂久久| 国产精品一二三区在线看| 欧美日韩在线观看h| 特大巨黑吊av在线直播| 在线观看一区二区三区| 亚洲av在线观看美女高潮| 最近最新中文字幕免费大全7| 国产日韩欧美在线精品| 国产精品免费大片| 欧美高清成人免费视频www| 久久人人爽av亚洲精品天堂 | 在线观看免费高清a一片| 夫妻性生交免费视频一级片| 18禁裸乳无遮挡免费网站照片| 人人妻人人澡人人爽人人夜夜| 视频中文字幕在线观看| 免费看不卡的av| 一级毛片电影观看| 亚洲国产精品999| 久久99热这里只频精品6学生| 九草在线视频观看| 久久97久久精品| 免费av不卡在线播放| 日韩欧美精品免费久久| 亚洲欧美精品自产自拍| 欧美精品亚洲一区二区| av在线观看视频网站免费| 91精品国产九色| 搡女人真爽免费视频火全软件| 老女人水多毛片| 国产亚洲欧美精品永久| 亚洲av成人精品一区久久| 一边亲一边摸免费视频| 国产午夜精品一二区理论片| 久久人人爽av亚洲精品天堂 | 久久精品久久精品一区二区三区| 性高湖久久久久久久久免费观看| 一区二区三区乱码不卡18| 成人毛片60女人毛片免费| 久久人人爽人人片av| 国产精品无大码| 国产欧美日韩一区二区三区在线 | 大香蕉久久网| 好男人视频免费观看在线| 免费观看在线日韩| 水蜜桃什么品种好| 街头女战士在线观看网站| 久久久久久人妻| 各种免费的搞黄视频| 在线观看免费视频网站a站| 一级二级三级毛片免费看| 国产成人精品福利久久| 18禁裸乳无遮挡免费网站照片| 两个人的视频大全免费| 免费在线观看成人毛片| 观看av在线不卡| 中文字幕人妻熟人妻熟丝袜美| 大片电影免费在线观看免费| 赤兔流量卡办理| 91在线精品国自产拍蜜月| 欧美日韩综合久久久久久| 国产片特级美女逼逼视频| 婷婷色麻豆天堂久久| 18禁动态无遮挡网站| 高清日韩中文字幕在线| 亚洲丝袜综合中文字幕| 深爱激情五月婷婷| 五月开心婷婷网| 大香蕉97超碰在线| 亚洲精品视频女| 亚洲国产成人一精品久久久| 国产精品一及| 日韩欧美一区视频在线观看 | 老司机影院成人| 汤姆久久久久久久影院中文字幕| 18禁动态无遮挡网站| 丰满人妻一区二区三区视频av| 久热这里只有精品99| 超碰av人人做人人爽久久| 久久久久久久久久久免费av| 亚洲四区av| 一区二区三区精品91| 国产久久久一区二区三区| 国产亚洲91精品色在线| 97超碰精品成人国产| 卡戴珊不雅视频在线播放| 亚洲欧美精品自产自拍| 人妻系列 视频| 一区二区av电影网| 日韩电影二区| 黄色怎么调成土黄色| 欧美区成人在线视频| 精品一区二区三区视频在线| 国产精品福利在线免费观看| 亚洲美女搞黄在线观看| 大片电影免费在线观看免费| 高清视频免费观看一区二区| videossex国产| 22中文网久久字幕| 成人二区视频| 中国三级夫妇交换| 久久毛片免费看一区二区三区| 啦啦啦视频在线资源免费观看| 亚洲第一区二区三区不卡| 99热6这里只有精品| 日韩精品有码人妻一区| 日韩视频在线欧美| 天堂8中文在线网| 国产av码专区亚洲av| 国产中年淑女户外野战色| 成人国产麻豆网| 成年女人在线观看亚洲视频| 精品少妇久久久久久888优播| 你懂的网址亚洲精品在线观看| 免费在线观看成人毛片| 精品久久久久久电影网| 午夜免费观看性视频| 高清不卡的av网站| 人妻夜夜爽99麻豆av| 香蕉精品网在线| 国产男人的电影天堂91| 色5月婷婷丁香| 成人无遮挡网站| 亚洲av国产av综合av卡| 亚洲图色成人| 亚洲国产欧美人成| 大香蕉久久网| 丝袜脚勾引网站| 久久精品久久久久久噜噜老黄| 联通29元200g的流量卡| 校园人妻丝袜中文字幕| 国产成人精品久久久久久| 欧美丝袜亚洲另类| 精品国产乱码久久久久久小说| 免费少妇av软件| 校园人妻丝袜中文字幕| 亚洲欧美一区二区三区黑人 | 久久久久精品性色| 国产黄频视频在线观看|